Abbisko Cayman Limited ( (HK:2256) ) has shared an update.
Abbisko Cayman Limited announced that its founder, Dr. Xu Yao-Chang, who also serves as the executive director, CEO, and chairman, has increased his shareholding in the company by purchasing 45,000 ordinary shares. This move, reflecting Dr. Xu’s confidence in the company’s growth prospects, raises his total shareholding to approximately 11.76% of the company’s issued shares. The transaction complies with relevant regulations, ensuring a sufficient public float and adherence to securities transaction codes, indicating a positive outlook for stakeholders.
More about Abbisko Cayman Limited
Abbisko Cayman Limited is a company incorporated in the Cayman Islands, operating within the pharmaceutical industry. The company focuses on the development and commercialization of innovative therapies, with a market focus on addressing unmet medical needs.
YTD Price Performance: 31.09%
Average Trading Volume: 2,827,122
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$4.1B
See more data about 2256 stock on TipRanks’ Stock Analysis page.